Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Introduction
Shattuck Labs, Inc. is a clinical-stage biotechnology company that is pioneering the development of dual-action fusion proteins, a new class of biologic medicines. Utilizing their proprietary Agonist Redirected Checkpoint (ARC®) platform, the company is dedicated to designing bi-functional fusion proteins capable of simultaneously inhibiting immune checkpoints and activating costimulatory pathways. This approach is instrumental in reactivating anti-tumor immune responses and modulating autoimmune mechanisms, addressing significant unmet needs in oncology and autoimmune disorders.
Innovative Technology and Platform
The core of Shattuck Labs’ innovation lies in its proprietary ARC® platform, which enables the rational design of fusion proteins with a dual mechanism of action. By targeting key immune checkpoints such as CD47 and PD-1 while concurrently stimulating costimulatory receptors like CD40 and OX40, the company is able to enhance the efficacy of immune-mediated treatments without the need for multiple separate therapies. This strategic integration of inhibitory and agonistic functions within a single molecule sets the company apart in the competitive biotechnology landscape.
Product Pipeline and Clinical Programs
Shattuck Labs is actively advancing several clinical programs with its innovative fusion protein candidates:
- SL-172154 (SIRPα-Fc-CD40L): Designed to block inhibitory checkpoints and stimulate immune activation, this candidate is undergoing early-phase clinical evaluation to address advanced cancer indications.
- SL-279252 (PD1-Fc-OX40L): Developed in collaboration with a major pharmaceutical partner, this compound exemplifies the company’s commitment to designing fusion proteins that combine checkpoint inhibition with costimulatory activation.
- Gamma Delta T Cell Engager Platform: Known as gadlen™, this innovative approach aims to bridge gamma delta T cells to tumor antigens, thereby enhancing the immune system’s ability to target and destroy cancer cells.
Throughout these programs, Shattuck Labs maintains a balanced focus on therapeutic innovation, clinical safety, and efficacy, which is thoroughly reflected in their robust preclinical data and ongoing Phase 1 clinical studies.
Market Position and Competitive Landscape
In the dynamic field of biotechnology, Shattuck Labs has carved out a unique niche by leveraging advanced protein engineering and novel therapeutic strategies. The company’s dual-action approach not only positions it as an innovator in the development of biologic medicines but also enables it to address complex diseases with limited treatment options. With clinical programs targeting both hematologic malignancies and autoimmune conditions, Shattuck Labs stands as a significant contributor in the realm of precision immunotherapy and therapeutic innovation.
Expertise, Experience, and Corporate Profile
With offices located in Austin, Texas and Durham, North Carolina, Shattuck Labs benefits from a strong foundation in regional biotech hubs known for their robust research and development ecosystems. The company’s leadership and scientific teams bring extensive expertise in protein engineering, immuno-oncology, and drug development. Their work not only reflects a deep understanding of molecular biology and immune regulation but also underscores a disciplined approach to clinical development that is critical for advancing novel therapeutics safely and effectively.
Understanding the Bi-Functional Fusion Protein Approach
At the heart of Shattuck Labs’ operations is the concept of a bi-functional fusion protein – a therapeutic designed to perform two critical functions within one molecule. This innovative approach allows for:
- Simultaneous inactivation of inhibitory checkpoints that normally prevent an effective immune response.
- Activation of costimulatory pathways that enhance the body's ability to combat cancer cells or manage autoimmune responses.
This dual mechanism is a testament to the company’s expertise in synthesizing complex biological data and leveraging cutting-edge protein design to create more potent therapies with a potentially improved safety profile.
Conclusion
Shattuck Labs, Inc. represents a forward-thinking force in the biotechnology industry. By integrating innovative dual-action fusion proteins with state-of-the-art research and a well-structured clinical development program, the company continues to bolster its position as an informed and experienced player in the field of biologic medicine. Investors and industry stakeholders will find that the company not only addresses pressing medical challenges but also exemplifies a commitment to scientific rigor and therapeutic innovation.
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's CEO, Taylor Schreiber, M.D., Ph.D., will deliver a presentation on April 9, 2025, at 3:00 PM EDT and participate in one-on-one meetings during the conference, which runs from April 7-10, 2025. A live webcast of the presentation will be accessible through the company's website, with a replay available for up to 30 days afterward.
Shattuck Labs (NASDAQ: STTK) reported its Q4 and full-year 2024 financial results, highlighting the advancement of SL-325, a potential first-in-class DR3 blocking antibody for inflammatory bowel diseases (IBD). The company presented favorable preclinical data at ECCO 2025, demonstrating safety and full receptor occupancy.
Key financial metrics include:
- Cash position of $73.0 million as of December 31, 2024
- Q4 2024 net loss of $18.7 million ($0.37 per share)
- Full-year 2024 net loss of $75.4 million ($1.49 per share)
- R&D expenses decreased to $67.2 million in 2024 from $74.3 million in 2023
The company terminated its SL-172154 program and is now focused on SL-325, with an IND filing expected in Q3 2025. Current cash runway is expected to fund operations into 2027.
Shattuck Labs (NASDAQ: STTK) announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325, their DR3 blocking antibody for inflammatory bowel disease (IBD) treatment. The study, presented at the 20th Congress of ECCO, demonstrated that SL-325 was well-tolerated in non-human primates with no evidence of toxicity or residual agonism.
The study evaluated safety, pharmacokinetics, pharmacodynamics, and immunogenicity over a 4-week dosing period followed by a 4-week recovery period. Three doses (1, 10, and 100 mg/kg) were administered intravenously, showing full and durable DR3 receptor occupancy at all dose levels. No adverse effects, infusion-related reactions, or organ dysfunction were observed, even at the highest dose of 100 mg/kg.
The company expects to file an IND in Q3 2025, with projected human dosing at 1 mg/kg Q2W through Q4W maintenance and 3 mg/kg Q2W through Q8W maintenance.
Shattuck Labs (NASDAQ: STTK) announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025, taking place in Berlin from February 19-22, 2025. The presentation will showcase results from IND-enabling toxicology studies of SL-325, their first-in-class DR3 blocking antibody, conducted in non-human primates.
Dr. Taylor Schreiber, CEO of Shattuck, will deliver the digital oral presentation titled 'Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel Disease' on February 20, 2025, at 6:15 PM CET. The presentation materials will be made available on the company's website after the event.
Shattuck Labs (NASDAQ: STTK) has announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress in San Francisco, California, scheduled for February 6-8, 2025. The presentation will focus on SL-325, a DR3-targeted, antagonistic antibody developed for the treatment of IBD.
The poster will be presented by Dr. Suresh de Silva, Shattuck's Co-Chief Scientific Officer, on Friday, February 7, 2025, from 5:00 PM to 6:30 PM PST at the Congress Exhibit Hall in The Moscone Center. The presentation materials will be made available on the company's website in the Events and Presentations section after the event.
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place in San Francisco from January 13-16, 2025.
Dr. Taylor Schreiber, CEO of Shattuck, will deliver a corporate update presentation on January 16, 2025, at 7:30 a.m. PT at The Westin St. Francis in the Elizabethan B room. The presentation will be available via live webcast on the company's website, with a replay accessible for up to 30 days afterward.
Shattuck Labs (NASDAQ: STTK) provided a corporate update highlighting key milestones for 2025, focusing on their DR3 blocking antibody program, SL-325. The company plans to present preclinical data at upcoming scientific conferences and expects several significant developments, including:
- GLP toxicology study data readout in Q1 2025
- IND filing in Q3 2025
- Phase 1 clinical trial initiation in Q3 2025
- DR3 bispecific development candidate nomination in H2 2025
The company reports a strong financial position with $90.1 million in cash, cash equivalents, and investments as of September 30, 2024, which is expected to fund operations into 2027. Management expressed optimism about SL-325's potential to achieve complete blockade of the DR3/TL1A signaling pathway based on non-human primate studies.
Shattuck Labs (NASDAQ: STTK), a biotechnology company developing novel therapeutics targeting TNF superfamily receptors for cancer and chronic immune-related diseases treatment, announced its participation in two upcoming investor conferences. The company's CEO, Dr. Taylor Schreiber, will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 12:30 p.m. ET, and participate in a fireside chat at the Evercore 7th Annual HealthCONx Conference on December 4, 2024, at 8:45 a.m. ET. Live webcasts will be available on the company's website with replays archived for up to 90 days.
Shattuck Labs (NASDAQ: STTK) reported Q3 2024 financial results and announced a strategic shift to focus on SL-325, a first-in-class DR3 blocking antibody. The company ended Q3 with $90.1 million in cash and investments, compared to $101.1 million year-over-year. Q3 net loss was $16.7 million ($0.33 per share), improved from $27.5 million ($0.65 per share) in Q3 2023. R&D expenses decreased to $16.3 million from $24.2 million, while G&A expenses reduced to $4.6 million from $5.1 million. The company completed restructuring plans and expects current cash to fund operations into 2027, beyond SL-325's Phase 1 trial results.
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD), with an IND filing expected in Q3 2025.
Key points:
- SL-172154 showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks
- Approximately 40% workforce reduction as part of restructuring
- Cash runway extended into 2027
- Mutual termination of collaboration agreement with Ono Pharmaceutical
- SL-325 demonstrates high affinity binding and superior efficacy over TL1A antibodies in preclinical studies
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is the core focus of Shattuck Labs, Inc.?
How does the ARC® platform work?
Which therapeutic areas does Shattuck Labs target?
What distinguishes Shattuck Labs from other biotech companies?
Can you elaborate on the company’s product pipeline?
Does Shattuck Labs collaborate with other companies?
